Quintiles has a wealth of experience in population pharmacokinetic (PK) / pharmacodynamic (PD) modelling and simulation.

Over the past ten years, its team of scientists has worked on more than 60 population PK/PD modelling projects involving 45 compounds across 13 different therapeutic areas and resulting in 20 new drug application (NDA) submissions.

A paper published by the US Food and Drug Administration (FDA) revealed that of 31 NDAs submitted over a 15-month period, a pharmacometrics component such as population PK/PD modelling and simulation was ranked as important in the decision-making process.